Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune checkpoint inhibitor therapy, according to a preclinical study led by researchers at Weill Cornell Medicine. The findings suggest a potential strategy for enhancing the potency of anticancer immunotherapies.
Dr. Ekta Khurana Wins New Starr Cancer Consortium Grant!
October 29, 2024
New Starr Cancer Consortium Grants Awarded to Weill Cornell Medicine Researchers
October 30, 2024
Three teams led by Weill Cornell Medicine scientists have received awards from the Starr Cancer Consortium in its 17th and final annual grant competition. The grants will fund research on the deep mechanisms of common cancers and related treatment strategies.
A Fully Automated AI-Based System for Assessing IVF Embryo Quality
October 23, 2024
A new artificial intelligence-based system can accurately assess the chromosomal status of in vitro-fertilized (IVF) embryos using only time-lapse video images of the embryos and maternal age, according to a study from investigators at Weill Cornell Medicine.
EIPM Member Dr. Silvia Formenti Elected to National Academy of Medicine!
October 22, 2024
EIPM Member Dr. Silvia Formenti Elected to National Academy of Medicine!
Dr. Silvia Formenti, chair of the Department of Radiation Oncology and the Sandra and Edward Meyer Professor of Cancer Research at Weill Cornell Medicine has been elected to the National Academy of Medicine.
Study Uncovers Mutations and DNA Structures Driving Bladder Cancer
October 10, 2024
How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center. The researchers found that antiviral enzymes that mutate the DNA of normal and cancer cells are key promoters of early bladder cancer development, and that standard chemotherapy is also a potent source of mutations.
Five Questions for EIPM’s Clinical Director Dr. Cora N. Sternberg about how Artificial Intelligence has impacted oncology.
October 9, 2024
Question: Please tell us how the use of AI-based tools has improved oncology literature searches?
AI’s Promise in Bladder Cancer Care
October 8, 2024
The article below was repurosed from Bladder Cancer Matters, a podcast of the Bladder Cancer Advocacy Network.
Five Questions for EIPM's Director Olivier Elemento, Ph.D. on Artificial Intelligence and Precision Medicine.
October 7, 2024
Englander Institute for Precision Medicine’s Director Olivier Elemento, Ph.D. on Artificial Intelligence and Precision Medicine. #AIWeek
How is AI used at the EIPM?
EIPM's 3Q 2024 Newsletter
October 7, 2024
October 4, 2024
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our third quarterly external newsletter of 2024!
Researchers Develop Insights into KRAS Mutations in Pancreatic Cancers
October 4, 2024
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to less invasiveness and weaker biological activity, according to a multicenter study conducted at Weill Cornell Medicine, NewYork-Presbyterian,